These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23393915)

  • 1. A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysis.
    Buti S; Donini M; Lazzarelli S; Passalacqua R
    Acta Biomed; 2012 Aug; 83(2):88-94. PubMed ID: 23393915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.
    Buti S; Donini M; Bersanelli M; Gattara A; Leonardi F; Passalacqua R
    Drugs R D; 2017 Dec; 17(4):585-596. PubMed ID: 28895069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases.
    Makino K; Yoda K; Tomoishi J; Kume H
    BMC Res Notes; 2014 Dec; 7():872. PubMed ID: 25471941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.
    Kondo T; Takagi T; Kobayashi H; Iizuka J; Nozaki T; Hashimoto Y; Ikezawa E; Yoshida K; Omae K; Tanabe K
    Jpn J Clin Oncol; 2014 Mar; 44(3):270-7. PubMed ID: 24474815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
    Najjar YG; Mittal K; Elson P; Wood L; Garcia JA; Dreicer R; Rini BI
    Eur J Cancer; 2014 Apr; 50(6):1084-9. PubMed ID: 24559686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib.
    Miyake H; Harada K; Miyazaki A; Fujisawa M
    Med Oncol; 2015 Mar; 32(3):78. PubMed ID: 25698532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma.
    Ohzeki T; Fukasawa S; Komaru A; Namekawa T; Sato Y; Takagi K; Kobayashi M; Uemura H; Ichikawa T; Ueda T
    Int J Urol; 2014 Oct; 21(10):1065-8. PubMed ID: 24930736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients.
    Neri B; Vannini A; Brugia M; Muto A; Rangan S; Rediti M; Tassi R; Cerullo C
    Int J Urol; 2013 May; 20(5):478-83. PubMed ID: 23113655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma.
    Guida FM; Santoni M; Conti A; Burattini L; Savini A; Zeppola T; Caricato M; Cascinu S; Tonini G; Santini D
    Crit Rev Oncol Hematol; 2014 Dec; 92(3):208-17. PubMed ID: 25151214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Alternative prescription schedules of sunitinib in metastatic kidney cancer: from the underground to the light?].
    Thiery-Vuillemin A; Mouillet G; Pouessel D; Barthelemy P; Caty A; Sebbagh S; Vanno YA; Laplaige P; Cheverau C; Ravaud A
    Bull Cancer; 2014 Sep; 101(9):832-40. PubMed ID: 25295955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell carcinoma: at least 12-month follow-up.
    Zhang CJ; Zhao PJ; Li XS; Zhao J; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; He ZS; Jin J; Zhou LQ
    Chin Med J (Engl); 2013; 126(15):2826-9. PubMed ID: 23924450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.
    Bracarda S; Negrier S; Casper J; Porta C; Schmidinger M; Larkin J; Gross Goupil M; Escudier B
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):227-233. PubMed ID: 28044472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The safety and efficacy of sunitinib using a modified regimen (2 weeks on/1 week off) for treatment of metastatic renal cell carcinoma].
    Togo Y; Shimatani K; Hanasaki T; Yo T; Nakanishi Y; Nagasawa S; Hashimoto T; Shiraishi Y; Taoka R; Suzuki T; Go S; Higuchi Y; Kanematsu A; Nojima M; Tsuchihashi K; Makino Y; Shimizu Y; Kanamaru S; Kono Y; Matsumoto K; Utsunomiya N; Ito N; Kawakita M; Yamamoto S
    Hinyokika Kiyo; 2014 May; 60(5):209-14. PubMed ID: 24894855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and tolerability of a sunitinib 3-week administration schedule in metastatic renal cell carcinoma patients: report of three cases.
    Neri B; Vannini A; Tassi R; Brugia M; Rangan S; Rediti M; Cerullo C
    Oncol Res; 2012; 20(5-6):259-64. PubMed ID: 23581233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma.
    Iwamoto K; Ishihara H; Takagi T; Kondo T; Yoshida K; Iizuka J; Tanabe K
    Med Oncol; 2018 Apr; 35(6):78. PubMed ID: 29687160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
    Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
    Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib 4/2 Versus 2/1 Schedule for Patients With Metastatic Renal Cell Carcinoma: Tertiary Care Hospital Experience.
    Ezz El Din M
    Clin Genitourin Cancer; 2017 Jun; 15(3):e455-e462. PubMed ID: 28392154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
    Eichelberg C; Heuer R; Chun FK; Hinrichs K; Zacharias M; Huland H; Heinzer H
    Eur Urol; 2008 Dec; 54(6):1373-8. PubMed ID: 18692304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia.
    Crumbaker M; Guminski A; Gurney H; Sabanathan D; Wong S; Pavlakis N
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e45-e49. PubMed ID: 28429452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.